28
2026-09
InxMed and Chugai Enter into a Worldwide License Agreement for SPYK04, a RAF-MEK Molecular Glue
HONG KONG and TOKYO, September 29, 2026 -- InxMed (Hong Kong) Limited (hereafter “InxMed”) and Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter “Chugai”) today announced that they have entered into a worldwide license agreement regarding SPYK04, a RAF-MEK molecular glue discovered by Chugai for the treatment of solid tumors.
28
2026-08
NANJING, China, August 28, 2026, -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective focal adhesion kinase (FAK) inhibitor, in combination with garsorasib (D-1553), a potent KRAS G12C inhibitor, in previously treated KRAS G12C-mutant metastatic colorectal cancer (CRC), have been published online in The Lancet Oncology.
09
2026-07
NANJING, China, July 9, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective focal adhesion kinase (FAK) inhibitor, in combination with garsorasib (D-1553), a potent KRASG12C inhibitor in first-line KRASG12C-mutant NSCLC, have been published online in The Lancet Respiratory Medicine.
01
2025-06
InxMed Co., Ltd, a clinical-stage biotechnological company, pioneering therapies to transform cancer treatment, released latest clinical data from a Phase Ib/II clinical trial (NCT06166836; NCT05379946) to evaluate the efficacy and safety of ifebemtinib (IN10018), an oral focal adhesion kinase (FAK) inhibitor in combination with garsorasib (D-1533), an oral KRAS G12C inhibitor, in KRAS G12C mutant solid tumors.
12
2024-11
NANJING, China, Nov 8, 2024 -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis, is presenting preclinical data at 15th Annual World ADC Conference in San Diego regarding ifebemtinib (ifebe, IN10018), a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), to enhance efficacy and improve safety of ADCs, and IN30758，a First-in-class ADC for treatment of multiple solid tumors including DXD resistant cancers.
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE